News

Diet, supplements, and over-the-counter medications play a crucial role in mitigating the daily symptoms of Parkinson’s, which can range from low energy levels to constipation to anxiety and depression, according to a presentation hosted by The Parkinson Voice Project. Susan Imke, FNP, GNP-C, a certified gerontological nurse practitioner who focuses…

The winners of a crowd-sourced research challenge designed to improve the ability of remote sensors to monitor Parkinson’s disease (PD) used a mix of signal processing and deep neural networks to better predict disease and disease severity. Sage Bionetworks, in collaboration with the…

Voyager Therapeutics will soon initiate a global Phase 2/3 clinical trial program to evaluate its VY-AADC gene therapy for the treatment of advanced Parkinson’s disease. The trial follows approval by the U.S. Food and Drug Administration of the company’s investigational new drug (IND) application…

Repetitive transcranial magnetic stimulation (TMS) does not appear to treat depressive symptoms in patients with Parkinson’s disease, although it may improve motor symptoms, an analysis of nine clinical trials found. But the study included relatively few patients, so the researchers, with Guangxi University of Science and Technology in China, said that their conclusions warrant further exploration…

A new technology that reduces “shaky hands” in people with essential tremor (ET) may benefit those with Parkinson’s disease. People with essential tremor, a condition that has overlapping motor features with Parkinson’s disease, have a significant reduction in their quality of life, as everyday tasks such as drinking from a…

The Parkinson’s Foundation has enrolled the 10,000th patient in the largest clinical trial of the disease yet to be conducted. Among the critical discoveries so far, the research has shown that regular visits to neurologists, more exercise, and more attention to mental health could help improve patients’ wellbeing. The…

Defects in mitochondria, the cell’s microscopic powerhouses, might actually protect Parkinson’s disease patients, a Norwegian study suggests. The findings show that, contrary to all current theories, deficiencies in complex I — a key component of mitochondria — exist randomly throughout the brains of Parkinson’s patients, not only in affected regions. In…

Levodopa improves Parkinson’s patients’ symptoms by binding with two types of receptors for dopamine, a neurotransmitter that helps regulate movement and emotional response. Although it is considered the gold standard in Parkinson’s treatment, a study from Binghamton University students contends that levodopa’s interaction with the dopamine receptor D2 may cause involuntary…

Mutations in the LRRK2 gene, a major genetic factor contributing to Parkinson’s disease, may likely affect the risk for Crohn’s disease, an inflammatory bowel disease, researchers at Mount Sinai in New York discovered. The results suggest a potential genetic link between Crohn’s disease and Parkinson’s and common disease…

An Axovant Sciences therapy for Parkinson’s disease showed signs of effectiveness, but an Alzheimer’s treatment did not, according to separate Phase 2 clinical trials. Nelotanserin, the therapy candidate for Parkinson’s disease dementia (PDD) associated with hallucinations and for Dementia with Lewy Bodies (DLB), appeared safe as well as displaying signs of effectiveness,…